CGC
Canopy Growth Corporation
CGC lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
CGC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Under pressure | |
| Unavailable |
CGC's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
CGC PE Valuation
CGC has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
CGC Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
CGC has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
CGC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.53 | +$1.38 |
| Q2 2026 | -$0.47 | +$2.47 |
| Q1 2026 | -$0.60 | +$3.31 |
| Q4 2025 | -$1.25 | +$2.52 |
| Q3 2025 | -$1.91 | +$2.92 |
| Q2 2025 | -$2.94 | +$3.87 |
| Q1 2025 | -$3.91 | +$2.27 |
| Q4 2024 | -$3.77 | +$6.37 |
CGC has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
CGC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $57.2M | +22% |
| Q2 2026 | $57.1M | +13% |
| Q1 2026 | $50.1M | +9.6% |
| Q4 2025 | $52.4M | -0.3% |
| Q3 2025 | $46.9M | +5.9% |
| Q2 2025 | $50.7M | +8.9% |
| Q1 2025 | $45.7M | -11% |
| Q4 2024 | $52.6M | -4.8% |
CGC's revenue is recovering but still below its 2020 peak: $57M last quarter, up 22% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -28% | -2.9 points |
| Q2 2026 | -27% | +4.1 points |
| Q1 2026 | -134% | -106 points |
| Q4 2025 | -35% | -3.5 points |
| Q3 2025 | -25% | +48 points |
| Q2 2025 | -31% | +13 points |
| Q1 2025 | -28% | +119 points |
| Q4 2024 | -32% | +45 points |
CGC's operating margin was −28% last quarter, down 2.9 points from the same quarter a year ago.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over CGC on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over CGC on profitability, with a higher operating margin.
CGC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$10.9M | +$2.6M |
| Q2 2026 | -$18.1M | -$9.9M |
| Q1 2026 | -$13.5M | +$11.9M |
| Q4 2025 | -$13.4M | +$6.4M |
| Q3 2025 | -$13.5M | +$26.2M |
| Q2 2025 | -$8.2M | +$31M |
| Q1 2025 | -$25.5M | -$9.8M |
| Q4 2024 | -$19.8M | +$3.5M |
CGC has burned cash in almost every quarter: −$56M over the past year, against −$67M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over CGC on cash generation, producing positive trailing cash flow while its opponent burns cash.
CGC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +846K shares |
| 1 year | +125% | +235M shares |
| 3 years | +770% | +374M shares |
| 5 years | +1035% | +386M shares |
CGC has 423M diluted shares, up 125% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over CGC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
CGC Net Leverage
CGC's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
CGC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 24.5 | Oversold |
| Stochastic | 6.6 | Oversold |
CGC's weekly RSI is 25 (oversold) and its Stochastic is 7 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
CGC PE vs Healthcare Sector
| Metric | CGC | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
CGC has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
CGC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.74 | 23% below |
| 20 week MA | $0.88 | 35% below |
| 50 week MA | $1.02 | 44% below |
| 100 week MA | $1.25 | 54% below |
| 200 week MA | $4.80 | 88% below |
CGC is in a downtrend: it's below all five of its weekly moving averages, and 88% below its 200-week average.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
CGC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $192.1 | $258.6 | +35% |
| 2021 | $258.6 | $96.2 | -63% |
| 2022 | $96.2 | $23.3 | -76% |
| 2023 | $23.3 | $5.11 | -78% |
| 2024 | $5.11 | $2.78 | -46% |
| 2025 | $2.78 | $1.19 | -57% |
| 2026 YTD | $1.19 | $0.57 | -52% |
CGC has finished five years in a row lower, and it's down 52% so far in 2026.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over CGC on returns for 2026, with the stronger performance.